Ripretinib
Qinlock (ripretinib) is a small molecule pharmaceutical. Ripretinib was first approved as Qinlock on 2020-05-15. It is used to treat gastrointestinal stromal tumors in the USA. The pharmaceutical is active against mast/stem cell growth factor receptor Kit and platelet-derived growth factor receptor alpha. Qinlock’s patents are valid until 2032-06-07 (FDA).
Trade Name |
Qinlock |
---|---|
Common Name |
ripretinib |
ChEMBL ID |
CHEMBL4216467 |
Indication |
gastrointestinal stromal tumors |
Drug Class |
Retinol derivatives; tyrosine kinase inhibitors |
Image (chem structure or protein)
$4,995
Want to know more?
Schedule a demo or contact us for additional purchasing options.
Every Drug Dataset Includes...
Full dataset compatible with-

SQL for web applications

R for statistical modeling

Spotfire & Tableau for visualization

CSV export file format

JSON export file format

XLSX export file format
Continually updated information available as a yearly subscription for individual drug-of-interest.